Inoue H, Kobayashi H, Itoh Y, Shinohara S
Department of Radiology, Faculty of Medicine, Kagoshima University, Japan.
Acta Radiol. 1989 Nov-Dec;30(6):603-8.
Sixty-one patients with liver metastases were treated with hepatic arterial injection of Adriamycin/Mitomycin C oil suspension (ADMOS). The liver metastases originated from the gastrointestinal tract in 41 patients and from other organs in 20 patients. Sixty-nine liver tumors were analyzed in these 61 patients. Computed tomography (CT) after ADMOS injection (Lip-CT) gave more information in 19 cases (31%) than enhanced CT with a water-soluble contrast medium. With Lip-CT, Lipiodol tumor enhancement was observed in 64 of 69 lesions. The patterns of Lipiodol uptake in the tumors were classified into 4 types: Homogeneous accumulation (20%), heterogeneous accumulation (16%); accumulation with a central defect (57%); and no accumulation (7%). A tumor response was achieved in 41 of 69 lesions (59%). Anticancer effects were also shown as a decrease in serum CEA levels. The one year survival rate estimated by the Kaplan-Meier method was 43 per cent and the median survival time was 337 days. The results were better among patients who received multiple doses of ADMOS. Only minimal side effects were associated with ADMOS. The method is considered to be an excellent diagnostic and therapeutic procedure for liver metastases.
61例肝转移患者接受了肝动脉注射阿霉素/丝裂霉素C油混悬液（ADMOS）治疗。41例患者的肝转移灶起源于胃肠道，20例患者的肝转移灶起源于其他器官。对这61例患者的69个肝肿瘤进行了分析。注射ADMOS后的计算机断层扫描（CT）（脂质CT）在19例（31%）患者中提供的信息比水溶性造影剂增强CT更多。通过脂质CT，在69个病灶中的64个观察到碘油肿瘤强化。肿瘤中碘油摄取模式分为4种类型：均匀聚集（20%）、不均匀聚集（16%）、有中心缺损的聚集（57%）和无聚集（7%）。69个病灶中的41个（59%）出现了肿瘤反应。抗癌效果还表现为血清癌胚抗原（CEA）水平降低。采用Kaplan-Meier法估计的1年生存率为43%，中位生存时间为337天。接受多剂量ADMOS治疗的患者结果更好。ADMOS仅伴有轻微副作用。该方法被认为是治疗肝转移的一种优秀的诊断和治疗方法。
